MAZE THERAPEUTICS, INC. Revenue
MAZE THERAPEUTICS, INC. (MAZE) reported Revenue of $20.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- MAZE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $20.00M.
- MAZE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- MAZE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $0.00.
- MAZE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $167.50M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $20.00M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $20.00M 10-Q · filed 2026-05-12 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.50M derived: sum of 2 quarters · filed 2026-03-25 | $167.50M derived: sum of 3 quarters · filed 2026-03-25 | $167.50M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.50M 10-Q · filed 2025-11-06 | $167.50M derived: sum of 2 quarters · filed 2025-11-06 | $167.50M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $165.00M 10-Q · filed 2025-08-12 | $165.00M 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |